Scholarlink

<p>Bronchiectasis is increasingly recognized as a chronic inflammatory airway disease involving persistent immune dysregulation, recurrent infection, and progressive lung tissue damage. Older adults bear a particularly high burden of bronchiectasis, as age-related changes such as immunosenescence, multimorbidity, and polypharmacy complicate disease management in this population. Anti-inflammatory therapies are emerging as a central component of treatment strategies, reflecting the growing understanding of inflammation as a key driver of disease progression. However, applying these therapies to older populations requires considering altered pharmacokinetics and pharmacodynamics, increased susceptibility to adverse effects, and comorbid conditions. This review examines current and emerging anti-inflammatory treatments for bronchiectasis, focusing on their relevance, safety, and limitations in older patients. Attention is given to the roles of neutrophilic and type 2 inflammatory pathways, as well as the challenges of implementing precision medicine approaches for older people.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-Specific Considerations in Bronchiectasis Management: Focus on Older Adults with Emphasis on Anti-inflammatory Treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Maria Gabriella Matera,
  • Vito De Novellis,
  • Raffaella Pagliaro,
  • Vincenzo Parente,
  • Fabio Perrotta,
  • Mario Cazzola

摘要

Bronchiectasis is increasingly recognized as a chronic inflammatory airway disease involving persistent immune dysregulation, recurrent infection, and progressive lung tissue damage. Older adults bear a particularly high burden of bronchiectasis, as age-related changes such as immunosenescence, multimorbidity, and polypharmacy complicate disease management in this population. Anti-inflammatory therapies are emerging as a central component of treatment strategies, reflecting the growing understanding of inflammation as a key driver of disease progression. However, applying these therapies to older populations requires considering altered pharmacokinetics and pharmacodynamics, increased susceptibility to adverse effects, and comorbid conditions. This review examines current and emerging anti-inflammatory treatments for bronchiectasis, focusing on their relevance, safety, and limitations in older patients. Attention is given to the roles of neutrophilic and type 2 inflammatory pathways, as well as the challenges of implementing precision medicine approaches for older people.